These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 32715339)
1. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339 [TBL] [Abstract][Full Text] [Related]
2. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Kattner AS; Holler E; Holler B; Klobuch S; Weber D; Martinovic D; Edinger M; Herr W; Wolff D Ann Hematol; 2020 Apr; 99(4):847-853. PubMed ID: 32086584 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis. Denk A; Mittermaier C; Weber D; Fante M; Güneş S; Edinger M; Herr W; Wolff D Ann Hematol; 2024 Sep; 103(9):3755-3764. PubMed ID: 38916742 [TBL] [Abstract][Full Text] [Related]
4. Abatacept as salvage therapy in chronic graft-versus-host disease-a retrospective analysis. Wertheimer T; Dohse M; Afram G; Weber D; Heidenreich M; Holler B; Kattner AS; Neubauer A; Mielke S; Ljungman P; Holler E; Herr W; Edinger M; Martínez AP; Fante M; Wolff D Ann Hematol; 2021 Mar; 100(3):779-787. PubMed ID: 33515310 [TBL] [Abstract][Full Text] [Related]
5. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y Front Immunol; 2021; 12():673636. PubMed ID: 34276662 [TBL] [Abstract][Full Text] [Related]
6. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus. Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756 [TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239 [TBL] [Abstract][Full Text] [Related]
8. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915 [TBL] [Abstract][Full Text] [Related]
9. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907 [TBL] [Abstract][Full Text] [Related]
10. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. Spina F; Radice T; De Philippis C; Soldarini M; Di Chio MC; Dodero A; Guidetti A; Viviani S; Corradini P Leuk Lymphoma; 2019 Jan; 60(1):101-109. PubMed ID: 29716416 [TBL] [Abstract][Full Text] [Related]
12. Therapy of chronic graft-versus-host disease. Arora M Best Pract Res Clin Haematol; 2008 Jun; 21(2):271-9. PubMed ID: 18503992 [TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. DeFilipp Z; Li S; Kempner ME; Brown J; Del Rio C; Valles B; Hunnewell C; Saylor M; Vanderklish J; Dey BR; El-Jawahri A; McAfee SL; Spitzer TR; Chen YB Biol Blood Marrow Transplant; 2018 Sep; 24(9):1836-1840. PubMed ID: 29758393 [TBL] [Abstract][Full Text] [Related]
14. Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation-a retrospective analysis on seven patients. Lamby P; Wolff D; Mielke S; Grigoleit GU; Ljungman P; Hilgendorf I; Holler E; Holler B; Weber D; Herr W; Schiltz D; Klein S; Graf S; Bjornhagen-Safwenberg V; Dolderer J; Prantl L Ann Hematol; 2019 Aug; 98(8):1867-1875. PubMed ID: 30993415 [TBL] [Abstract][Full Text] [Related]
15. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780 [TBL] [Abstract][Full Text] [Related]
16. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Akpek G; Lee SM; Anders V; Vogelsang GB Biol Blood Marrow Transplant; 2001; 7(9):495-502. PubMed ID: 11669216 [TBL] [Abstract][Full Text] [Related]
17. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease. Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430 [TBL] [Abstract][Full Text] [Related]
18. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation]. Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286 [No Abstract] [Full Text] [Related]
19. A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure. White J; Elemary M; Linn SM; Novitzky-Basso I; Culos S; Tan SK; Kelly K; Deotare U; Xenocostas A; Hamad N; Law A; Kumar R; Kim DDH Transplant Cell Ther; 2023 Feb; 29(2):120.e1-120.e9. PubMed ID: 36460202 [TBL] [Abstract][Full Text] [Related]
20. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]